Investment analysts at JPMorgan Chase & Co. initiated coverage on shares of Precigen (NASDAQ:PGEN – Get Rating) in a research report issued to clients and investors on Tuesday, The Fly reports. The brokerage set a “neutral” rating on the biotechnology company’s stock. A number of other equities analysts have also issued reports on PGEN. HC […]